TABLE 1.
Severity of lung impairment
| Author | Year | Type of TB | Mild (%) | Moderate (%) | Severe (%) | Any impairment (%) | Severity classification used by authors | ||
| Moderate | Moderately severe | Severe | Very severe | ||||||
| Akkara et al. [47]# | 2013 | TB | 21.5 | 37.2 | 41.3 | 86.8 | ATS | ||
| Báez-Saldaña et al. [69]# | 2013 | TB | 13 | 3 | 5 | 1.5 | 1.5 | 41 | ATS/ERS |
| Baig et al. [74]# | 2010 | TB | 5.9 | 23 | 69.2 | 100 | GOLD | ||
| Bemba et al. [76] (obstruction) | 2017 | TB | 4.9 | 0 | 4.9 | 68.7 | ATS/ERS | ||
| Bemba et al. [76] (restriction) | 2017 | TB | 34.9 | 25.2 | 14.6 | 68.7 | ATS/ERS | ||
| Bemba et al. [76] (mixed) | 2017 | TB | 0 | 6.8 | 8.7 | 68.7 | ATS/ERS | ||
| Chin et al. [77]# | 2019 | TB (MDR) | – | 64 | 14 | 35 | GLI 2012 | ||
| Chushkin et al. [28]# | 2017 | TB | 2.8 | 15.9 | 9.3 | 47.6 | ATS/ERS | ||
| Daniels et al. [29]# | 2019 | TB | 20 | 10 | 50 | 10 | 48 | GOLD | |
| Di Naso et al. [31] (DS TB) | 2011 | TB (DS) | 53.3 | 13.3 | 13.3 | 80 | NA | ||
| Di Naso et al. [31] (MDR TB) | 2011 | TB (MDR) | 8.3 | 16.7 | 75 | 100 | NA | ||
| Fiogbe et al. [32] (obstruction) | 2019 | TB (DS) | 23 | 10 | 0 | 45 | ATS/ERS | ||
| Fiogbe et al. [32] (restriction) | 2019 | TB (DS) | 3.2 | 6 | 1 | 45 | ATS/ERS | ||
| Fiogbe et al. [32] (mixed) | 2019 | TB (DS) | 0 | 0 | 2.1 | 45 | GOLD | ||
| Hwang et al. [36]# | 2014 | TB | 45 | 43.7 | 11.3 | NA | GOLD | ||
| Khosa et al. [8] (obstruction) | 2020 | TB (DS) | 1.6 | – | – | 64.5 | Criée et al. [91] | ||
| Khosa et al. [8] (restriction) | 2020 | TB (DS) | 27.4 | 22.6 | – | 64.5 | Criée et al. [91] | ||
| Khosa et al. [8] (mixed) | 2020 | TB (DS) | – | 1.6 | 11.3 | 64.5 | Criée et al. [91] | ||
| Mancuzo et al. [44] (obstruction) | 2020 | TB | 21.4 | 4.5 | 0.5 | 63 | Pereira [92] | ||
| Mancuzo et al. [44] (restriction) | 2020 | TB | 16.7 | 0.3 | 1.3 | 63 | Pereira [92] | ||
| Mancuzo et al. [44] (mixed) | 2020 | TB | 3.2 | 7.7 | 7.4 | 63 | Pereira [92] | ||
| Manji et al. [45] (obstruction) | 2016 | TB | 56 | 23 | 21 | 74 | ATS/ERS/NLHEP | ||
| Manji et al. [45] (restriction) | 2016 | TB | 43 | 30 | 27 | 74 | ATS/ERS/NLHEP | ||
| Mattila et al. [48]# | 2017 | TB | 10 | 57 | 38 | NA | GOLD | ||
| Nuwagira et al. [51]# | 2020 | TB (MDR) | 0 | 55 | 45 | NA | GOLD | ||
| Ojuawo et al. [52] (obstruction) | 2020 | TB | 1.9 | 3.9 | 0 | 0 | 0 | 72 | ATS/ERS |
| Ojuawo et al. [52] (restriction) | 2020 | TB | 5.2 | 22.1 | 0 | 8.4 | 6.5 | 72 | ATS/ERS |
| Ojuawo et al. [52] (mixed) | 2020 | TB | 0 | 0 | 4.5 | 13.6 | 5.8 | 72 | ATS/ERS |
| Osman et al. [53]# | 2016 | TB | 8.3 | 58.3 | 16.7 | 16.7 | NA | GOLD | |
| Ralph et al. [62] | 2013 | TB (DS and MDR) | – | 27 | NA | Pellegrino et al. [93] | |||
| Macedo Ramos et al. [42] | 2006 | TB | 29.4 | 22.6 | 23.6 | 76 | Brazilian Society of Pulmonology and Phthisiology 2000 | ||
| Santra et al. [64]# | 2017 | TB | 12 | 52 | 44 | 30 | 100 | GOLD | |
| Vecino et al. [72] | 2011 | TB (DS and MDR) | – | 11 | 9 | 52 | ATS and Cocchiarella et al. [94] | ||
The denominator used to calculate the proportion of subjects with a specific severity grade of impairment types varied among the studies, e.g. denominator=total study population with both normal and impaired lung function combined versus denominator=only participants with lung impairment. #: Only the severity of pulmonary obstruction was presented in the respective manuscript. ATS: American Thoracic Society; DS: drug susceptible; ERS: European Respiratory Society; GLI: Global Lung Function Initiative; GOLD: Global Initiative for Chronic Obstructive Lung Disease; MDR: multidrug resistant; NA: not applicable; NLHEP: National Lung Health Education Program; TB: tuberculosis.